Tevogen (TVGN) Assets (2021 - 2026)
Tevogen's (TVGN) quarterly Assets came in at $4.9 million in Q1 2026, up 20.81% on a YoY basis from $4.1 million in Q1 2025, and up 12.27% quarter-over-quarter from $4.4 million in Q4 2025.
Analysis
Tevogen (TVGN) Assets (2021 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Assets for 6 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 20.81% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 20.81% YoY), and the FY2025 full-year result was $4.4 million, up 26.61% from the prior year.
- Assets rose to $4.9 million in Q1 2026 per TVGN's latest filing, from $4.4 million in the prior quarter.
- Across five years, Assets topped out at $357.1 million in Q4 2022 and bottomed at $3.3 million in Q2 2024.
- Historically, Assets has averaged $90.5 million across 5 years, with a median of $4.9 million in 2026.
- The sharpest annual moves came in 2023 and 2025: Assets tumbled 98.46% in 2023, then gained 28.97% in 2025.
- Over 5 years, Assets stood at $357.1 million in 2022, then sank by 98.46% to $5.5 million in 2023, then slumped by 37.12% to $3.5 million in 2024, then grew by 26.61% to $4.4 million in 2025, then increased by 12.27% to $4.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $4.9 million, $4.4 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 1.50 Bn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 2.65 Bn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 915.53 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 1.75 Bn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 985.10 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 1.39 Bn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 170.30 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.19 Bn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 502.87 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 4.92 Mn |
| Dec 31, 2025 | 4.38 Mn |
| Sep 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.07 Mn |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | 4.29 Mn |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 3.36 Mn |
| Dec 31, 2023 | 5.51 Mn |
| Sep 30, 2023 | 26.41 Mn |
| Jun 30, 2023 | 26.38 Mn |
| Mar 31, 2023 | 25.47 Mn |
| Dec 31, 2022 | 357.14 Mn |
| Sep 30, 2022 | 354.54 Mn |
| Jun 30, 2022 | 352.98 Mn |
| Mar 31, 2022 | 352.83 Mn |
| Dec 31, 2021 | 352.85 Mn |